The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PVCT | -54.36% | -17% | -3.66% | -95% |
| S&P | +13% | +86.41% | +13.26% | +519% |
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treat several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.
Do short-sellers have these three stocks pegged? You be the judge!
Down by double digits in just a few days. Why these 3 health-care stocks were the most horrendous performers this week.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.00M | -100.4% |
| Gross Margin | 99.19% | 0.1% |
| Market Cap | $37.40M | -9.0% |
| Market Cap / Employee | $6.23M | 0.0% |
| Employees | 6 | 50.0% |
| Net Income | -$1.32M | -30.5% |
| EBITDA | -$1.17M | -54.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.07M | -88.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.12M | 0.0% |
| Short Term Debt | $2.33M | -16.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -1085.67% | -842.6% |
| Return On Invested Capital | 66.52% | -16.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.84M | -48.6% |
| Operating Free Cash Flow | -$0.84M | -48.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -9.28 | -7.04 | -6.15 | -6.36 | 16.49% |
| Price to Sales | 81.79 | 63.90 | 68.43 | 106.74 | 87.96% |
| Price to Tangible Book Value | -9.28 | -7.04 | -6.15 | -6.36 | 16.46% |
| Enterprise Value to EBITDA | -23.43 | -45.25 | -20.06 | -34.07 | -40.71% |
| Total Debt | $3.18M | $2.58M | $2.51M | $2.44M | -12.78% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
